Shares of Ireland-based Prothena Corporation (PRTA) have fallen by 38% over the past year and by over 60% over the past five years. Recently, the stock price jumped 26% on news that well-known healthcare institutional investor EcoR1 Capital disclosed a 23.6% stake.
A quick glance at the company showed that it was trading for under the value of its cash position, with multiple irons in the fire including an intriguing program (partnered with Roche (RHHBY)) targeting Parkinson's disease with key data readout expected next year. I look forward to digging deeper and